GMAB Genmab A/S ADS Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
22:30
Aug 08
Aug 08
Notes upcoming catalysts from analyst reports
Notes upcoming catalysts for the tickers based on Cowen and UBS reports, no directional view stated.
MED
11:22
Aug 07
Aug 07
GMAB valuation clouded by Merus debt
Speaker notes valuation complexity at GMAB following a large debt-financed acquisition of Merus; no directional commitment made.
LOW
16:20
Jul 26
Jul 26
Author discloses Genmab as one of their top 5 current holdings.
Author discloses Genmab as one of their top 5 current holdings, indicating an active long position with personal conviction.
MED
17:51
Jul 14
Jul 14
The author is compiling a list of follower-requested stocks for future review without.
The author is compiling a list of follower-requested stocks for future review without expressing any current positions or trade ideas.
LOW
07:31
Jul 05
Jul 05
The author lists 23 stocks he plans to review after receiving suggestions from followers.
The author lists 23 stocks he plans to review after receiving suggestions from followers, with no current position or directional view expressed.
LOW
11:33
Jun 30
Jun 30
Pre-market movers include Apple and Google flat on UK CMA probe.
Pre-market movers include Apple and Google flat on UK CMA probe, CNXC plunging 24% on weak outlook, DLR falling 5% on data center deal, AVAV surging 28% on earnings beat, GMAB rising 8% on positive trial results, ABBV and MRK dipping on House investigation, and LCII up 7% on merger with Patrick Industries.
20:39
Jun 08
Jun 08
Ticker mentioned as a reminder in a GLP-1 discussion, no directional view or catalyst stated.
LOW
17:30
Jun 02
Jun 02
The author disagrees with an M&A hypothesis for ABVX by citing GMAB's acquisition of Merus.
The author disagrees with an M&A hypothesis for ABVX by citing GMAB's acquisition of Merus during phase 3 as a counterexample, but does not state a personal position.
LOW
22:01
Jun 01
Jun 01
Notes GMAB receives ~15% royalties from JNJ's Darzalex, a key revenue driver for the company.
LOW
14:27
May 12
May 12
Long $GMAB (Genmab) — paired with HALO as a Darzalex revenue capture play.
Long $GMAB (Genmab) — paired with HALO as a Darzalex revenue capture play; speaker holds both as siphons on Darzalex sales.
MED
04:28
Feb 17
Feb 17
A sell-side analyst is initiating coverage on GMAB with a price target.
A sell-side analyst is initiating coverage on GMAB with a price target, indicating a bullish forward-looking view on the stock.
MED
About GMAB Analyst Coverage
Buzzberg tracks GMAB (Genmab A/S ADS) across 5 sources. 2 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (18%). 11 total trade ideas tracked. Latest voices: seedy19tron, frenchv33921, __con_.